Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
akcea therapeutics
boston blog main
4
×
boston top stories
inotersen
4
×
life sciences
4
×
national blog main
national top stories
new york blog main
new york top stories
patisiran
4
×
san diego blog main
san diego top stories
tafamidis
alnylam pharmaceuticals
boston
clinical trials
drugs
fda
hereditary transthyretin amyloidosis
onpattro
pfizer
rna interference
san francisco blog main
san francisco top stories
vyndaqel
andrew fire
anylam pharmaceuticals
barry greene
biotech
boston university
cardiomyopathy
craig mello
dan ollendorf
european medicines agency
harvard pilgrim health care
institute for clinical and economic review
john berk
john maraganore
mary o'donnell
neuropathy
What
alnylam
fda
drug
medicine
ago
approved
patients
rna
rnai
uses
afternoon
akcea
alnylam’s
amyloidosis
approve
approves
attr
available
awaits
battle
biological
cells
crossed
debilitating
decades
decision
discovered
disease
ema
employ
europe
fingers
follows
friday
gene
genetic
gets
harmful
historic
history
Language
Current search:
inotersen
×
" boston blog main "
×
" life sciences "
×
patisiran
×
@xconomy.com
5 years ago
FDA OKs Pfizer Rare Disease Drug, Sets Up Battle With Alnylam, Akcea
@xconomy.com
6 years ago
RNAi Hits Europe as EMA Follows FDA, Approves Alnylam Drug
@xconomy.com
6 years ago
Alnylam Gets Landmark FDA OK For First-Ever RNAi Drug
@xconomy.com
6 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision